These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 399483)

  • 1. Using bibliometric analyses of patent literature for predicting the clinical fates of developing drugs.
    Windsor DA
    J Chem Inf Comput Sci; 1979 Nov; 19(4):218-21. PubMed ID: 399483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the leading patent equivalents services.
    Johns TM; Andrus WG; De Voe S; Myers J; Smith RG; Uhlir O
    J Chem Inf Comput Sci; 1979 Nov; 19(4):241-6. PubMed ID: 551974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-to-patent does not predict first- or best-in-class: analysis of approved small molecule vs. biologic drugs.
    Roland GE; Xu JJ; Wagner JA
    Clin Pharmacol Ther; 2015 Jan; 97(1):19-21. PubMed ID: 25670379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinventing nonpatent literature for pharmaceutical patenting.
    Atkinson KH
    Pharm Pat Anal; 2015; 4(5):371-5. PubMed ID: 26389649
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamics of global disclosure through patent and journal publications for biopharmaceutical products.
    Thangaraj H; van Dolleweerd CJ; McGowan EG; Ma JK
    Nat Biotechnol; 2009 Jul; 27(7):614-8. PubMed ID: 19587663
    [No Abstract]   [Full Text] [Related]  

  • 6. Patent highlights October-November 2017.
    Mucke HA
    Pharm Pat Anal; 2018 Mar; 7(2):73-81. PubMed ID: 29417883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Companies use value-based pricing for single-source off-patent drugs.
    Thompson CA
    Am J Health Syst Pharm; 2016 Mar; 73(6):350, 352, 355. PubMed ID: 26953277
    [No Abstract]   [Full Text] [Related]  

  • 8. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Getting the most out of your IP--patent management along its life cycle.
    Bader MA; Gassmann O; Ziegler N; Ruether F
    Drug Discov Today; 2012 Apr; 17(7-8):281-4. PubMed ID: 22079191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patent laws: could changes enhance drug development?
    Mattes JA
    Arch Gen Psychiatry; 1997 Oct; 54(10):970. PubMed ID: 9337779
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical patent challenges--time for reassessment?
    Glass G
    Nat Rev Drug Discov; 2004 Dec; 3(12):1057-62. PubMed ID: 15573104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Lewis RA
    J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987
    [No Abstract]   [Full Text] [Related]  

  • 13. Examining the applicability of market forecasting models to new pharmaceutical products.
    Agrawal M; Calantone RJ
    Health Mark Q; 1996; 13(4):17-31. PubMed ID: 10159642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent patent applications in drug screening.
    Nat Biotechnol; 2007 Aug; 25(8):869. PubMed ID: 17687360
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent protection for protein structure analysis.
    Shimbo I; Nakajima R; Yokoyama S; Sumikura K
    Nat Biotechnol; 2004 Jan; 22(1):109-12. PubMed ID: 14704710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Patents and availability of essential drugs].
    Carné X
    Med Clin (Barc); 2007 Nov; 129(16):617-8. PubMed ID: 18001674
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent portfolio management: literature review and a proposed model.
    Conegundes De Jesus CK; Salerno MS
    Expert Opin Ther Pat; 2018 Jun; 28(6):505-516. PubMed ID: 29718747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatological drug development.
    Ehmann CW
    Arch Dermatol; 1988 Jun; 124(6):950-1. PubMed ID: 3377525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.